Jacobs Levy Equity Management, Inc Tcr2 Therapeutics Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$1.86 - $3.75 $155,049 - $312,600	83,360 New	83,360 $150,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $490,296 - $962,205	-204,290 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $935,648 - $1.7 Million	204,290 New	204,290 $952,000
Q4 2020 Feb 16, 2021	SELL	$19.0 - $32.63 $679,592 - $1.17 Million	-35,768 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$13.1 - $20.69 $79,975 - $126,312	-6,105 Reduced 14.58%	35,768 $727,000
Q2 2020 Aug 17, 2020	BUY	$6.51 - $16.85 $272,593 - $705,560	41,873 New	41,873 $643,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.